The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The impact of an evolving first-line setting on subsequent treatment lines in multiple myeloma
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses how evolving first-line treatments for multiple myeloma (MM) impact subsequent therapy. As more patients receive lenalidomide and anti-CD38 therapies initially, second-line treatments must be effective for those potentially refractory to both. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Amgen, Sanofi, Regeneron, Celgene, Menarini, Takeda, GSK, BMS, Janssen, Beigene, Swixx, Astra Zeneca.
